Pharmaceutical News

RSS

Repros Therapeutics receives further clarification on the Full Clinical Hold status of Proellex

Repros Therapeutics today announced that the Company has received further clarification from the Food and Drug Administration (FDA) on the Full Clinical Hold status of Proellex.

29 Sep 2009

IP Advocate founder to speak on commercialization barriers faced by university faculty inventors

Speaking of the then-divided Berlin, former President Reagan famously admonished Soviet leader Gorbachev to “tear down this wall.” In a similar spirit, IP Advocate founder Dr. Renee Kaswan is calling on the university technology transfer system to remove the barriers that keep innovations from moving swiftly into the marketplace.

29 Sep 2009

Sciele Pharma files NDA for glycopyrrolate oral solution

Sciele Pharma, Inc., a Shionogi company, today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for glycopyrrolate oral solution to treat chronic, moderate-to-severe drooling in pediatric patients. This condition often results from cerebral palsy as well as from other neurological disorders.

29 Sep 2009

Journal publishes Hythiam's PROMETA treatment program results

Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies.

29 Sep 2009

Oculus launches Microcyn Skin & Wound HydroGel OTC

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.

29 Sep 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

AAPS Annual Meeting to discuss new research and technologies in pharmaceutical sciences

More than 8,500 individuals from the field of pharmaceutical research are expected to attend this year's AAPS Annual Meeting and Exposition November 8 - 12, 2009 at the Los Angeles Convention Center in California.

29 Sep 2009

BDI Pharma's proprietary flu vaccine supply program SecuriFLU successful

BDI Pharma, Inc., the fastest growing national wholesale distributor of biotech therapies, announced today the success of its proprietary supply program SecuriFLU. The program provides ordering solutions for customers who require quick, easy access to online ordering for flu vaccine. Customers may access brands from multiple manufacturers offering a full range of age indications.

29 Sep 2009

Walk-in flu shots to lure customers into drugstores

Americans may be as likely to get a flu shot at one of the nation's largest pharmacy chains as in a doctor's office or clinic. That should not be surprising, according to healthcare market research publisher Kalorama Information. The nation's major drugstores have been using flu shot programs to earn revenue and to draw customers in the store to make other purchases, an indirect revenue strategy that Kalorama Information predicted in its reports on the retail clinic phenomenon in recent years.

29 Sep 2009

New measles vaccination methods to reduce costs and improve safety

Worldwide, there are estimated to be 10 million cases of measles and 197,000 deaths from the disease each year. While vaccines exist to protect children against measles, the vaccines are often difficult to store, costly to transport and may be prone to contamination when shipped to developing countries.

29 Sep 2009

Flu shots available at Concentra Urgent Care locations

The flu season is in full swing, and health officials predict this year’s outbreak of seasonal influenza to be stronger than usual. To help protect against this highly contagious illness, Concentra is offering seasonal flu vaccines at more than 300 medical centers across the country.

29 Sep 2009

Additional countries to join in donating H1N1 vaccines to developing countries, U.N official says

Additional countries are expected to soon announce they will follow in the footsteps of nine developed countries who recently said they would donate H1N1 (swine flu) vaccine supplies to poorer nations, David Nabarro, of the U.N. said Friday, Reuters reports.

29 Sep 2009

SOHM launches 26 branded generic pharmaceutical products in India

SOHM, Inc., a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today the launch of 26 branded generic pharmaceutical products in India. The Company has already appointed two distributors in Northern India covering the largest state of India with a population of almost 1.5 billion people.

28 Sep 2009

UNC awarded $8.6M for a new Center for Integrated Systems Genetics

Autism, depression, anxiety. Antipsychotic drug side effects. What are the genetic and environmental factors that underlie and contribute to these complex problems? And how do genes and environment interact to shape them?

28 Sep 2009

MarkMonitor Brandjacking Index reveals growth in pharmaceutical brandjacking for popular drug brands

MarkMonitor®, the global leader in enterprise brand protection, today released the company’s latest Brandjacking Index®, which finds a parallel online system of pharmaceutical supply and demand fueled by continued growth in listings for pharmaceuticals on business-to-business (B2B) exchange sites as well as increased traffic to illicit pharmacies. The report also reveals a growth in pharmaceutical brandjacking for popular drug brands.

28 Sep 2009

Merck to distribute Afluria in the U.S. for CSL Biotherapies

CSL Biotherapies and its parent company, CSL Limited, one of the world's leading manufacturers of influenza vaccine, have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria® in the United States under an exclusive, six-year agreement effective September 3, 2009.

28 Sep 2009

European Commission grants conditional marketing authorization for Gilead's Cayston

Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.

28 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

Presentations on Inovio Biomedical's electroporation-delivered DNA vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th.

28 Sep 2009

WellPoint covers administration costs for H1N1 vaccines

Each year, influenza causes illness, hospitalizations and deaths, and severely strains the health care delivery system. This year, seasonal flu is complicated by the emergence and rapid spread of the H1N1 virus. In an effort to ensure that individuals and their families can take the appropriate actions to help protect themselves against the H1N1 virus, WellPoint's affiliated health plans will cover the administration of the H1N1 vaccine without co-pay or deductible for all health plan members. Plans also are encouraging self-insured employers to cover the cost of the vaccination for their employees.

28 Sep 2009